Novel RET Inhibitors Promising in Chinese Patients with RET-fusion Positive NSCLC

Second-Line Platinum-Doublet Regimens Reasonable in SCLC

Determining Adjuvant Therapy Through Recurrence Prediction: New Investigations

Keynote Addresses Lessons from SCLC Mouse Models

CDX Models Help Bring Personalized Treatment for SCLC a Step Closer

Preconditioning Program Shortens Postsurgical Hospital Stay for People with Lung Cancer

In Brief for February 9, 2022

In Brief for February 23, 2022

Low-Dose CT, ctDNA May Partner for Lung Cancer Detection

Award Lecture Highlights Tumor Evolution Through Liquid Biopsy

Panel Explores Emerging Treatments and Sequencing Strategies for Patients with Advanced NSCLCs Driven by Rare Oncogenes

Evidence Supports Adding Biological, Pathological, and Molecular Assessments to the TNM Lung Cancer Staging System